$45 billion for Genentech
Tuesday, 22 July, 2008
Swiss pharma giant Roche has offered to buy out the remaining 44 per cent of shares in US biotech Genentech for US$43.7 billion (A$45 billion).
Roche acquired a majority in Genentech in 1990 and currently owns 55.9 per cent of the San Francisco company, set up by biotech pioneer Herb Boyer in 1976. Genentech manufactures the blockbuster cancer drugs Herceptin and Avastin, among others.
Roche is offering US$89 per share in cash and is promising to respect Genentech's 'unique research culture' and headquarters.
Roche estimates that the combined entity will be the seventh largest US pharmaceuticals company in terms of market share and will generate more than US$15 billion in annual revenues.
Diabetes changes the structure of our hearts, study finds
Type 2 diabetes directly alters the heart's structure and energy systems, which explains why...
Beta blockers could halt triple negative breast cancer
Researchers have identified a molecular biomarker in triple negative breast cancer tumours which...
Common arthritis drug also lowers blood pressure
Scientists have known for a while that methotrexate helps with inflammation, but it may also help...
